Ahmedabad, Lincoln Pharmaceuticals Ltd., one of India’s leading healthcare companies, reported a revenue of Rs. 21.61 crore as against a net profit of Rs. 17.60 crore showing a growth of 22.79 percent over the net profit. Lincoln Pharmaceuticals Ltd reports 22.8% rise in the Standalone Net Profit at Rs. 21.6 crore in Q3 FY23
Net income from operations during the third quarter of financial year 2023 was Rs. 140.12 crore which was Rs. 122.52 crore was 14.37 percent higher than the net revenues. The company during the third quarter of the financial year 2023 Rs. 33.11 crores EBITA was reported
Which in the same period of last financial year was Rs. 26.09 crore showing an increase of 26.92 percent over EBITA. During the third quarter of financial year 2023, EPS per share will be Rs. 10.79 per share which in the same period of last financial year was Rs. was 8.79.
During the current financial year, the company received WHO-GMP approval for tablet, capsule, dry-powder suspension products at its cephalosporin plant at Mehsana, Gujarat. Capacity expansion at the plant has also been completed and commercial production is expected to start from March 2023.
Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited said, “The company posted good numbers during the quarter, maintaining good margins and profitability.
Recently, the company received approval from Australia’s medicine and medical devices regulator, the Therapeutic Goods Administration (TGA), for its Khatraj plant. TGA and EU GMP approval will strengthen the company’s position in the export market. Strategic growth initiatives, product and geographic expansion, higher efficiencies will maximize value creation for all stakeholders in the near to medium term.”